{"id":50160,"date":"2025-12-08T20:51:13","date_gmt":"2025-12-08T12:51:13","guid":{"rendered":"https:\/\/flcube.com\/?p=50160"},"modified":"2025-12-08T20:51:14","modified_gmt":"2025-12-08T12:51:14","slug":"sirnaomics-chempartner-galahead-nucleic-acid-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50160","title":{"rendered":"Sirnaomics ChemPartner GalAhead Nucleic-Acid Deal"},"content":{"rendered":"\n<p><strong>Sirnaomics Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2257:HKG\">HKG: 2257<\/a>) announced a global non\u2011exclusive licensing agreement with<strong> ChemPartner Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/300149:SHE\">SHE: 300149<\/a>)<\/strong>, focusing on <strong>GalAhead<\/strong> and related nucleic acid drug delivery technology platforms to create a comprehensive service channel for small nucleic acid drug development.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-agreement-overview-amp-strategic-focus\">Agreement Overview &amp; Strategic Focus<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Sirnaomics Ltd. (2257.HK) + ChemPartner<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Global non-exclusive licensing<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>GalAhead delivery platform + nucleic acid drug delivery<\/td><\/tr><tr><td><strong>Target Organ<\/strong><\/td><td>Liver-targeted delivery<\/td><\/tr><tr><td><strong>Key Features<\/strong><\/td><td>Long-acting drug administration capabilities<\/td><\/tr><tr><td><strong>ChemPartner Role<\/strong><\/td><td>CRO\/CDMO providing full-cycle integrated services<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-galahead-platform-amp-technology-differentiation\">GalAhead Platform &amp; Technology Differentiation<\/h2>\n\n\n\n<p><strong>Sirnaomics&#8217; GalAhead Platform:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Liver-Targeted Delivery<\/strong>: Specifically designed for hepatic tissue targeting<\/li>\n\n\n\n<li><strong>Long-Acting Formulation<\/strong>: Meets requirements for extended dosing intervals<\/li>\n\n\n\n<li><strong>Nucleic Acid Focus<\/strong>: Optimized for siRNA, antisense oligonucleotides, and other RNA therapeutics<\/li>\n\n\n\n<li><strong>Competitive Edge<\/strong>: Addresses key delivery challenges in nucleic acid drug development<\/li>\n<\/ul>\n\n\n\n<p><strong>ChemPartner&#8217;s Contribution:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Full-Cycle CRO\/CDMO<\/strong>: Covers discovery through commercial manufacturing<\/li>\n\n\n\n<li><strong>Integrated Services<\/strong>: Streamlines development process for biotech partners<\/li>\n\n\n\n<li><strong>Platform Synergy<\/strong>: Combines delivery technology with development expertise<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-market-impact\">Strategic Rationale &amp; Market Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Strategic Goal<\/th><th>Mechanism<\/th><th>Expected Outcome<\/th><\/tr><\/thead><tbody><tr><td><strong>Comprehensive Service Channel<\/strong><\/td><td>Integrate GalAhead with ChemPartner&#8217;s CRO\/CDMO<\/td><td>End-to-end nucleic acid drug development capability<\/td><\/tr><tr><td><strong>Industry Empowerment<\/strong><\/td><td>Provide accessible delivery technology platform<\/td><td>Accelerate innovation across biotech sector<\/td><\/tr><tr><td><strong>Global Expansion<\/strong><\/td><td>Non-exclusive licensing enables multiple partnerships<\/td><td>Drive high-quality development of nucleic acid therapeutics<\/td><\/tr><tr><td><strong>Quality Development<\/strong><\/td><td>Combine technology strengths<\/td><td>Establish new standard for RNA therapeutic development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Nucleic Acid Drug Market<\/strong>: Global market projected <strong>$15 billion<\/strong> by 2030, growing at <strong>25% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Delivery Challenge<\/strong>: Liver targeting remains key bottleneck; GalAhead addresses this specifically<\/li>\n\n\n\n<li><strong>CRO\/CDMO Demand<\/strong>: China biotech sector driving demand for integrated nucleic acid development services<\/li>\n\n\n\n<li><strong>Sirnaomics Portfolio<\/strong>: Company has multiple siRNA candidates in clinic; platform licensing diversifies revenue<\/li>\n\n\n\n<li><strong>ChemPartner Strategy<\/strong>: Partnership enhances capability in high-growth RNA therapeutics segment<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the collaboration&#8217;s impact on nucleic acid drug development, commercial prospects, and market penetration. Actual results may differ due to technology adoption rates, competitive dynamics, and regulatory uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sirnaomics Ltd. (HKG: 2257) announced a global non\u2011exclusive licensing agreement with ChemPartner Co., Ltd. (SHE:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50161,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[214,845,1020,440],"class_list":["post-50160","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-chempartner-pharmatech","tag-hkg-2257","tag-she-300149","tag-sirnaomics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sirnaomics ChemPartner GalAhead Nucleic-Acid Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sirnaomics Ltd. (HKG: 2257) announced a global non\u2011exclusive licensing agreement with ChemPartner Co., Ltd. (SHE: 300149), focusing on GalAhead and related nucleic acid drug delivery technology platforms to create a comprehensive service channel for small nucleic acid drug development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50160\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sirnaomics ChemPartner GalAhead Nucleic-Acid Deal\" \/>\n<meta property=\"og:description\" content=\"Sirnaomics Ltd. (HKG: 2257) announced a global non\u2011exclusive licensing agreement with ChemPartner Co., Ltd. (SHE: 300149), focusing on GalAhead and related nucleic acid drug delivery technology platforms to create a comprehensive service channel for small nucleic acid drug development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50160\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-08T12:51:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-08T12:51:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0803.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50160#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50160\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sirnaomics ChemPartner GalAhead Nucleic-Acid Deal\",\"datePublished\":\"2025-12-08T12:51:13+00:00\",\"dateModified\":\"2025-12-08T12:51:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50160\"},\"wordCount\":331,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50160#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0803.webp\",\"keywords\":[\"ChemPartner Pharmatech\",\"HKG: 2257\",\"SHE: 300149\",\"Sirnaomics\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50160#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50160\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50160\",\"name\":\"Sirnaomics ChemPartner GalAhead Nucleic-Acid Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50160#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50160#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0803.webp\",\"datePublished\":\"2025-12-08T12:51:13+00:00\",\"dateModified\":\"2025-12-08T12:51:14+00:00\",\"description\":\"Sirnaomics Ltd. (HKG: 2257) announced a global non\u2011exclusive licensing agreement with ChemPartner Co., Ltd. (SHE: 300149), focusing on GalAhead and related nucleic acid drug delivery technology platforms to create a comprehensive service channel for small nucleic acid drug development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50160#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50160\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50160#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0803.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0803.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sirnaomics ChemPartner GalAhead Nucleic-Acid Deal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50160#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sirnaomics ChemPartner GalAhead Nucleic-Acid Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sirnaomics ChemPartner GalAhead Nucleic-Acid Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Sirnaomics Ltd. (HKG: 2257) announced a global non\u2011exclusive licensing agreement with ChemPartner Co., Ltd. (SHE: 300149), focusing on GalAhead and related nucleic acid drug delivery technology platforms to create a comprehensive service channel for small nucleic acid drug development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50160","og_locale":"en_US","og_type":"article","og_title":"Sirnaomics ChemPartner GalAhead Nucleic-Acid Deal","og_description":"Sirnaomics Ltd. (HKG: 2257) announced a global non\u2011exclusive licensing agreement with ChemPartner Co., Ltd. (SHE: 300149), focusing on GalAhead and related nucleic acid drug delivery technology platforms to create a comprehensive service channel for small nucleic acid drug development.","og_url":"https:\/\/flcube.com\/?p=50160","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-08T12:51:13+00:00","article_modified_time":"2025-12-08T12:51:14+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0803.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50160#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50160"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sirnaomics ChemPartner GalAhead Nucleic-Acid Deal","datePublished":"2025-12-08T12:51:13+00:00","dateModified":"2025-12-08T12:51:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50160"},"wordCount":331,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50160#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0803.webp","keywords":["ChemPartner Pharmatech","HKG: 2257","SHE: 300149","Sirnaomics"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50160#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50160","url":"https:\/\/flcube.com\/?p=50160","name":"Sirnaomics ChemPartner GalAhead Nucleic-Acid Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50160#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50160#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0803.webp","datePublished":"2025-12-08T12:51:13+00:00","dateModified":"2025-12-08T12:51:14+00:00","description":"Sirnaomics Ltd. (HKG: 2257) announced a global non\u2011exclusive licensing agreement with ChemPartner Co., Ltd. (SHE: 300149), focusing on GalAhead and related nucleic acid drug delivery technology platforms to create a comprehensive service channel for small nucleic acid drug development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50160#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50160"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50160#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0803.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0803.webp","width":1080,"height":608,"caption":"Sirnaomics ChemPartner GalAhead Nucleic-Acid Deal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50160#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sirnaomics ChemPartner GalAhead Nucleic-Acid Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0803.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50160"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50160\/revisions"}],"predecessor-version":[{"id":50162,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50160\/revisions\/50162"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50161"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50160"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50160"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}